A primer on tumour immunology and prostate cancer immunotherapy.
作者信息
Ren Runhan, Koti Madhuri, Hamilton Thomas, Graham Charles H, Nayak Jasmir G, Singh Jas, Drachenberg Darrel E, Siemens D Robert
机构信息
Department of Urology, Queen's University, Kingston, ON, Canada;
Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada;
出版信息
Can Urol Assoc J. 2016 Jan-Feb;10(1-2):60-5. doi: 10.5489/cuaj.3418.
Abstract
摘要
相似文献
1
A primer on tumour immunology and prostate cancer immunotherapy.肿瘤免疫学与前列腺癌免疫治疗入门
Can Urol Assoc J. 2016 Jan-Feb;10(1-2):60-5. doi: 10.5489/cuaj.3418.
2
Immunology and immunotherapy approaches for prostate cancer.前列腺癌的免疫学与免疫治疗方法
Prostate Cancer Prostatic Dis. 2007;10(3):224-36. doi: 10.1038/sj.pcan.4500964. Epub 2007 Apr 10.
3
Advances in prostate cancer immunotherapy.
Surg Oncol. 2002 Jun;11(1-2):35-45. doi: 10.1016/s0960-7404(02)00012-9.
4
The immunotherapy of prostate and bladder cancer.前列腺癌和膀胱癌的免疫疗法。
BJU Int. 2005 Oct;96(5):728-35. doi: 10.1111/j.1464-410X.2005.05772.x.
5
[Prostate cancer microenvironment: Its structure, functions and therapeutic applications].
Prog Urol. 2016 Jun;26(8):464-76. doi: 10.1016/j.purol.2016.06.006. Epub 2016 Aug 8.
6
Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.外源性、内源性、肿瘤和免疫因素的综合分析，用于精准医学。
Gut. 2018 Jun;67(6):1168-1180. doi: 10.1136/gutjnl-2017-315537. Epub 2018 Feb 6.
7
Immunology and immunotherapy of human cancer: present concepts and clinical developments.人类癌症的免疫学与免疫疗法：当前概念与临床进展
Crit Rev Oncol Hematol. 2000 Apr;34(1):1-25. doi: 10.1016/s1040-8428(99)00059-1.
8
Prostate cancer: advances in immunotherapy.前列腺癌：免疫疗法的进展
BioDrugs. 2003;17(2):131-8. doi: 10.2165/00063030-200317020-00005.
9
The role of the tumour microenvironment in immunotherapy.肿瘤微环境在免疫治疗中的作用。
Endocr Relat Cancer. 2017 Dec;24(12):T283-T295. doi: 10.1530/ERC-17-0146. Epub 2017 Jul 28.
10
Target molecules in specific immunotherapy against prostate cancer.针对前列腺癌的特异性免疫疗法中的靶分子。
Int J Clin Oncol. 2003 Aug;8(4):193-9. doi: 10.1007/s10147-003-0332-x.
引用本文的文献
1
A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy.一种新型组蛋白去乙酰化酶抑制剂通过消除多形核髓系来源的抑制性细胞重塑肿瘤微环境，并使前列腺癌对免疫治疗敏感。
BMC Med. 2023 Oct 25;21(1):402. doi: 10.1186/s12916-023-03094-0.
2
Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition.前列腺癌的免疫原性通过 BET 溴结构域抑制增强。
J Immunother Cancer. 2019 Oct 25;7(1):277. doi: 10.1186/s40425-019-0758-y.
3
Technical Feasibility of Tissue Microarray (TMA) Analysis of Tumor-Associated Immune Response in Prostate Cancer.前列腺癌肿瘤相关免疫反应组织微阵列（TMA）分析的技术可行性
J Cancer. 2018 Jun 4;9(12):2191-2202. doi: 10.7150/jca.22846. eCollection 2018.
4
Transforming the prostatic tumor microenvironment with oncolytic virotherapy.通过溶瘤病毒疗法改变前列腺肿瘤微环境。
Oncoimmunology. 2018 Mar 27;7(7):e1445459. doi: 10.1080/2162402X.2018.1445459. eCollection 2018.
5
Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review.免疫疗法作为一种有前途的前列腺癌治疗方法：系统评价。
J Immunol Res. 2017;2017:4861570. doi: 10.1155/2017/4861570. Epub 2017 Oct 3.
6
Construction of a fusion plasmid containing the PSCA gene and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and its anti-tumor effect in an animal model of prostate cancer.构建含前列腺干细胞抗原（PSCA）基因和细胞毒性T淋巴细胞相关抗原4（CTLA-4）的融合质粒及其在前列腺癌动物模型中的抗肿瘤作用。
Braz J Med Biol Res. 2016 Oct 24;49(11):e5620. doi: 10.1590/1414-431X20165620.
本文引用的文献
1
Immune Infiltration and Prostate Cancer.免疫浸润与前列腺癌
Front Oncol. 2015 Jul 8;5:128. doi: 10.3389/fonc.2015.00128. eCollection 2015.
2
Evolutionary determinants of cancer.癌症的进化决定因素。
Cancer Discov. 2015 Aug;5(8):806-20. doi: 10.1158/2159-8290.CD-15-0439. Epub 2015 Jul 20.
3
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC).2015年加拿大泌尿外科协会-加拿大泌尿外科肿瘤学组去势抵抗性前列腺癌（CRPC）管理指南。
Can Urol Assoc J. 2015 Mar-Apr;9(3-4):90-6. doi: 10.5489/cuaj.2526.
4
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.纳武利尤单抗与伊匹木单抗联合用药或单药治疗初治黑色素瘤
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
5
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.癌症治疗中的免疫检查点靶向治疗：迈向具有治愈潜力的联合策略。
Cell. 2015 Apr 9;161(2):205-14. doi: 10.1016/j.cell.2015.03.030.
6
Immune-mediated mechanisms influencing the efficacy of anticancer therapies.影响抗癌疗法疗效的免疫介导机制。
Trends Immunol. 2015 Apr;36(4):198-216. doi: 10.1016/j.it.2015.02.006.
7
Neoantigens in cancer immunotherapy.肿瘤免疫治疗中的新生抗原
Science. 2015 Apr 3;348(6230):69-74. doi: 10.1126/science.aaa4971.
8
The future of immune checkpoint therapy.免疫检查点疗法的未来。
Science. 2015 Apr 3;348(6230):56-61. doi: 10.1126/science.aaa8172.
9
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.免疫疗法在泌尿系统肿瘤中的系统评价：CTLA-4、PD-1/PD-L1 和 HLA-G 靶向作用的不断演变。
Eur Urol. 2015 Aug;68(2):267-79. doi: 10.1016/j.eururo.2015.02.032. Epub 2015 Mar 29.
10
Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer.去势抵抗性前列腺癌的当前及新兴免疫疗法
Urology. 2015 May;85(5):976-986. doi: 10.1016/j.urology.2014.12.029. Epub 2015 Feb 20.
Zotero 插件